AHK-Cu (Alanine-Histidine-Lysine Copper) vs P-21 Peptide
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
AHK-Cu (Alanine-Histidine-Lysine Copper)
Copper-chelating tripeptide structurally related to GHK-Cu but optimized for scalp and hair follicle applications. AHK-Cu activates hair follicle stem cells and prolongs the anagen (active growth) phase, making it a key research compound for androgenetic alopecia and diffuse hair loss. Used topically as an alternative or complement to minoxidil and finasteride.
Full profileP-21 Peptide
Short neuropeptide based on the activity-dependent neurotrophic factor (ADNF) family with potent neuroprotective effects demonstrated in Alzheimer's disease models. Distinct from the cell cycle inhibitor protein p21/CDKN1A. Reduces amyloid-beta burden, improves cognitive outcomes in rodent models, and modulates neuroinflammation through STAT3 and JAK2 signaling pathways.
Full profile| AHK-Cu (Alanine-Histidine-Lysine Copper) | P-21 Peptide | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | AHK copper peptide, Ala-His-Lys copper, hair growth copper peptide, AHK-copper complex | P21, Colivelin fragment, P21 neuropeptide, ADNF-related neuropeptide |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 0.1%–1% %, Daily topical application (scalp) | 5mcg–20mcg mcg, daily or every other day (intranasal or SC) |
| Administration | Topical (scalp serum/solution), Subcutaneous (microneedling-assisted delivery) | Intranasal, Subcutaneous injection |
| Key side effects | Mild scalp irritation, Contact dermatitis (rare), Temporary scalp redness or tingling, Transient scalp shedding at initiation (shedding phase) | Limited human safety data, In animal studies: well-tolerated at therapeutic doses, Theoretical STAT3 pathway concerns with chronic use (pro-survival signaling), Nasal irritation (intranasal route) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: AHK-Cu (Alanine-Histidine-Lysine Copper) is research-stage, while P-21 Peptide is preclinical only.
- Administration: AHK-Cu (Alanine-Histidine-Lysine Copper) — Topical (scalp serum/solution), Subcutaneous (microneedling-assisted delivery); P-21 Peptide — Intranasal, Subcutaneous injection.
- Dosing units differ: AHK-Cu (Alanine-Histidine-Lysine Copper) is dosed in %, P-21 Peptide in mcg — they operate at different scales.
- Frequency: AHK-Cu (Alanine-Histidine-Lysine Copper) is typically Daily topical application (scalp); P-21 Peptide is daily or every other day (intranasal or SC).
How each works
AHK-Cu (Alanine-Histidine-Lysine Copper)
AHK-Cu activates β-catenin/Wnt signaling in dermal papilla cells and promotes VEGF expression around hair follicles. Studies demonstrate extended anagen phase duration, increased follicle size, and upregulation of hair growth factors in treated scalp tissue. The copper component supports tyrosinase activity for follicle pigmentation and metalloenzymes involved in extracellular matrix remodeling around follicles.
P-21 Peptide
P-21 activates STAT3/JAK2 signaling through CNTF-related pathways, reducing amyloid-beta toxicity by activating amyloid-clearing enzymes (insulin-degrading enzyme, neprilysin) and inhibiting tau phosphorylation. Derived from the colivelin family of neuroprotective peptides, P-21 demonstrates cognitive improvement in Alzheimer's mouse models at doses far below cytotoxic levels. Human data remains limited.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.